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Preleukemia: one name, many meanings
HP Koeffler1,2,3 and G Leong2
Definition of preleukemia has evolved. It was first used to describe the myelodysplastic syndrome (MDS) with a propensity to
progress to acute myeloid leukemia (AML). Individuals with germline mutations of either RUNX1, CEBPA, or GATA2 can also be called
as preleukemic because they have a markedly increased incidence of evolution into AML. Also, alkylating chemotherapy or
radiation can cause MDS/preleukemia, which nearly always progress to AML. More recently, investigators noted that AML patients
who achieved complete morphological remission after chemotherapy often have clonal hematopoiesis predominantly marked by
either DNMT3A, TET2 or IDH1/2 mutations, which were also present at diagnosis of AML. This preleukemic clone represents
involvement of an early hematopoietic stem cells, which is resistant to standard therapy. The same clonal hematopoietic mutations
have been identified in older ‘normal’ individuals who have a modest increased risk of developing frank AML. These individuals
have occasionally been said, probably inappropriately, to have a preleukemia clone. Our evolving understanding of the term
preleukemia has occurred by advancing technology including studies of X chromosome inactivation, cytogenetics and more
recently deep nucleotide sequencing.
Leukemia (2017) 31, 534–542; doi:10.1038/leu.2016.364
PRELEUKEMIA ASSOCIATED WITH MYELODYSPLASTIC
SYNDROME
The term ‘preleukemia’ has undergone a major evolution since it
was first used in 1953 by Block et al.1 At that time, the term
referred to the heterogeneous group of hematopoietic disorders
associated with a block in myeloid differentiation and chronic
cytopenias. We now call these disorders, myelodysplastic syn-
dromes (MDS).2–9 Prevalence of these abnormalities is markedly
increasing as our population ages; about 75 new patients per
100 000 individuals per year over the age of 65 years develop
MDS. About 20–30% of these individuals do indeed progress to
acute myeloid leukemia (AML); and thus, these individuals might
justifiably be known as preleukemic.
In the late 1960s and 1970s, one of the prominent advances in
our understanding of MDS/AML was the concept that the MDS/
leukemic event occurred in 1 stem cell, which had a hematopoie-
tic growth advantage causing a clonal population of MDS/
leukemic cells. This insight was based on the observation of
X-inactivation in females.10,11 Females have two X chromosomes;
between the 4th and 16th cell stage of blastogenesis, each
cell stochastically inactivates either its maternal or paternal X
chromosome. A number of methods have evolved to determine
which X chromosome has been inactivated.12,13 The initial
approach was pioneered by Ernest Beutler who utilized G6PD
isoenzymes.14–16 Over the years, additional methods were
developed to identify X-inactivation in females, with one of the
most versatile taking advantage of 2 features: cytosine methyla-
tion of the inactive X chromosome and different numbers of CAG
trinucleotides within the promoter region of the androgen
receptor, which resides on the X chromosome.17 This technique
allows interrogation of almost all females as opposed to a small
population of predominantly African Americans with G6PD
isoenzymes. Philip Fialkow’s group showed clonal hematopoiesis
occurred in a number of hematopoietic diseases including chronic
myelogenous leukemia, acute lymphocytic leukemia and AML.18
Also, Fialkow noted that in many cases of AML, the clonality
occurred in the myeloid compartment and not the lymphoid
compartment. MDS, in contrast, appeared to have an identical
clonality of both the myeloid and lymphoid compartments, albeit
the myeloid compartment appeared to have a major growth
advantage.19 This suggested that the MDS clone initiated in a very
early hematopoietic stem cell.
With the era of massively parallel nucleotide sequencing, we
have a fairly clear idea of the major mutations that affect patients
who have MDS, who evolve from MDS to AML (secondary AML,
sAML) and those with de novo AML (Table 1).4,5,20–28 Nine genes
occur more frequently in MDS than de novo AML (Table 1)
including four spliceosome genes that are mutated in 60–70%
of MDS cases, but these latter genes are mutated in fewer than
5–10% of de novo AML cases.29 These mutant genes are involved
in ineffective dysplastic hematopoiesis, not frank AML.
Mutations that are often observed in de novo AML are known as
Driver or pan-AML mutations including mutations of NPM1, FLT3,
IDH1, N/KRAS, RUNX1, CEBPA, WT1, PTPN11, c-KIT. For example,
NPM1 is rarely mutated in MDS, but occurs in 27% of de novo AML
cases. Likewise, chromosomal translocations (often a fusion of a
transcription factor gene with another gene) occur frequently in
de novo AML (18%). Examples include fusion of genes such as
RUNX1 with ETO, PML with RARA, CBFB with MYHII, as well as
fusion of MLL with various partner genes, which only rarely occur
in MDS (4%).30 These Driver mutations produce a major block in
differentiation providing a proliferative advantage to this clone of
cells.30
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Because cases of sAML evolves from MDS, these cells often
contained genes mutated in MDS (Table 1).30 Driver (pan-AML)
mutations are gained as MDS evolves to sAML.30 Of interest,
individuals with sAML achieve complete remission only about 50%
of the time and their event-free survival (EFS) is 4.2 months. In
contrast, 92% of de novo AML patients enter a complete remission,
and their EFS is ~ 15.7 months.30
OLIGOCLONAL HEMATOPOIESIS: NORMAL AGING VERSUS
PRELEUKEMIC CLONE
Analysis of X chromosome inactivation discovered skewing of X
chromosome inactivation (also known as Lyonization).31–34
X-inactivation during blastogenesis usually results in equal
inactivation of the maternal and paternal X chromosomes in the
female. Skewing represents unequal distribution of cells expres-
sing either the paternal and maternal allele of the female X
chromosome. It can occur during early embryogenesis, but rarely
deviates410%. However, X chromosomal skewing increases with
age approaching 20% of those who are 28–32 years old, and 40%
of those⩾ 60 years.10,12,13,32–34 A study in normal females ⩾ 75 of
age found that 56% of individuals had skewing of neutrophils and
40% had skewing of T-lymphocytes.34 Thus, older individuals have
hematopoietic cells that favor usage of one X allele. This has been
explained by unequal exhaustion of hematopoietic stem cells as
individuals age. This observation was buttress by genomically
marking murine hematopoietic stem cells and using them
for complete hematopoietic transplantation. Multiple clones of
hematopoiesis initially developed in these transplanted animals;
but as the mice aged, oligoclonal hematopoiesis predominated,
suggesting that with age, certain hematopoietic clones can
predominate.35 Of note, this phenomenon was not noted in
humans who underwent hematopoietic transplantation.36
SNP-Chip analysis of peripheral blood of 50 000 normal
individuals showed that copy-number changes in the genome
increased with increasing age; 40.5% of individuals from birth to
50 years of age had copy number alterations; but after age 50
years, the rate rose to about 2–3%.37 These copy-number changes
often occurred in genes that also are abnormal in MDS and AML.37
These individuals with copy-number changes had a 10-fold
increased risk of developing MDS or AML.37
Recently, a number of studies using high throughput nucleotide
sequencing confirmed what had been suggested by studies of
skewing of the inactive X-chromosome in normal elderly
individuals. On average, a normal appearing 60-, 70- and 90-
year-old individual has a 5%, 10% and 20% incidence, respectively,
of clonal hematopoiesis as marked by a mutation.38–40 A recent
study of a normal population of 50–60-year-old individuals found
with exceptionally deep sequencing that clonal hematopoiesis
occurred in 95% of individuals as marked by a mutation of either
DNMT3A or TET2.41 An interesting, unifying study found TET2
mutations in the blood of ten of 182 elderly ‘normal’ women who
also had chromosomal skewing of the X chromosome. In contrast,
105 normal women of the same age without X-chromosome
skewing, had no TET2 mutations.42 Mutation of DNMT3A occurs
about fivefold more frequently in the normal elderly individuals
than mutations of either TET2, IDH1/2, AXSL1, JAK2, SRSF2 or SF3B1
(to name a few). Many of these mutations of the normal elderly
are the same as those in the preleukemic clone identified in
complete remission of sAML, or found in the very early
hematopoietic stem cells in individuals with either MDS or AML
(both to be discussed).38–40,43 The base change of these mutations
was most commonly cytosine to thymine transition, which is a
somatic mutational signature of aging. Usually only one gene
and on rare occasions two or three genes are mutated; these
additional mutations occur more frequently as the ‘normal’
individual becomes older.38–40 On average, o20% and more
often o3% of either the peripheral blood or marrow cells are part
of the mutant hematopoietic clone in these elderly individuals
(also called variant allele frequency (VAF)).
For lack of a better nomenclature, this hematopoietic clone in
the elderly has occasionally been called an age-related preleu-
kemic clone; this is usually a misnomer. About 0.5 to 1% of these
individuals per year developed MDS/AML (hazard ratio 11.1–
12.9).38,39 The greater the number of different mutations or the
greater the contribution (VAF) of the mutant clone, the greater the
Table 1. Exome sequencing: mutational defects in MDS and sAML versus de novo AML
MDS sAML De novo AML
Gene Mutations (%) Gene Mutations (%) Gene Mutations (%)
TET2a 33 TET2a 20 FLT3b 28
→ SF3B1a 32 SF3B1a 11 NPM1b 27
ASXL1a 23 ASXL1a 32 DNMT3A 26
→ SRSF2a 17 SRSF2a 20 IDH1/2 10
→ZRSR2a 8 ZRSR2a 8 RUNX1b 9
EZH2 a 5 EZH2a 9 TET2 9
BCORa 4 BCORa 8 NRAS/KRASb 8
→U2AF1a 8 U2AF1a 16 TP53 8
STAG2a 8 STAG2a 14 CEBPAb 6
RUNX1 10 RUNX1b 31 WT1b 6
DNMT3A 13 NF1b 6 PTPN11b 5
IDH2/IDH1 5 NRAS/KRASb 31 KITb 4
TP53 6 TP53 15 U2AF1 4
FLT3 5 IDH1/2 20 KRASb 4
CBL 5 FLT3b 19 SMC1A 4
JAK2 5 DNMT3A 19 SMC3 4
BCOR 3 PTPN11b 5 PHF6 3
NRAS or KRAS 7 CEBPAb 3 STAG2 2
MPL 3 NPM1b 5 RAD21 2
NF1 3 SMC3 2 FAM5C 2
ATM 3 CBL 5 EZH2 1
→ , mutant spliceosome gene; sAML, secondary AML (MDS→AML). MDS data;9 sAML data;30 de novo AML data.26 aNotable difference of incidence during
MDS and sAML versus de novo AML. bDriver (Pan AML) mutations.
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chance to evolve into MDS/AML (for example, if the mutant clone
constitutes 410% of the hematopoietic population, these
individuals have at least a 1% risk per year of developing
AML39). Acquisition of a Driver (pan-AML) mutation(s) is required
for development of AML in these individuals with morphologically
normal marrow cells. These genes behave as the ‘gatekeepers’ of
leukemogensis providing, when mutated, the needed stimulus for
establishment of frank AML.
Thus as humans age, they often develop a hematopoietic clone
carrying a mutation of at least either DNMT3A, ASXL1, TET2 or IDH2,
but only a small minority of these individuals actually develop
myeloid malignancies. These Driver mutations provide a compe-
titive advantage to the hematopoietic stem cells compared with
normal hematopoiesis. Whether this mutant stem cell pool is more
receptive to secondary mutations requires further study.
Analogous phenomenon occur in the lymphoid system.
Monoclonal gammopathy of unknown significance (MGUS)
features a small accumulation of plasma cells producing a
monoclonal immunoglobulin.44 The aberrant clone of plasma
cells infrequently (1% per year) progresses to multiple myeloma.
Likewise, a clonal mature B-cell population can develop in older
individuals, which rarely progresses to chronic lymphocytic
leukemia.45 Incidence of all three of these clonal hematopoietic
conditions increase with age. Clonal abnormalities have been
noted in other tissue which otherwise appear normal. For
example, the normal sun-exposed eyelid frequently has mutations
including NOTCH1, NOTCH2, NOTCH3, FAT1, TP53 and RBM10; some
of these mutations are associated with clonal expansion of these
skin cells.46 Also, we and others noted years ago that the normal
appearing colon and lung near the tumor can harbored genomic
alterations (for example, aneuploidy, RAS mutations).47,48 These
too represent a precancerous genomic abnormality.
PRELEUKEMIA: GERMLINE MUTANT HEMATOPOIETIC CLONE
Twins studies have suggested familial clustering of AML;49,50 and a
large analysis of over 24 000 first-degree relatives of about 7000
patients with AML noted that if the proband develops MDS/AML
before the age of 25 years, the first-degree relative has an
increased risk of MDS and AML.51 Individuals with inherited
germline mutations of one of several transcription factors (RUNX1,
GATA2 or CEBPA) have an increased propensity to develop AML
over their life.52–56 Other inherited germline that can also
predispose to MDS includes Diamond–Blackfan anemia (20% risk
of MDS/AML), dyskeratosis congenita (disorder of telomere
maintenance, 30% risk MDS/AML), Fanconi anemia (40% risk),
severe congenital neutropenia (20–40% risk), Shwachman-
Diamond syndrome (10–35% risk), mutations of the SRP72 gene
(increased risk of aplastic anemia or MDS), Bloom syndrome (25%
risk for MDS/AML), Li-Fraumeni syndrome (p53 mutation) (5–7%
risk) and familial monosomy 7.57–59 For each of these inherited
germline mutation, their progression to frank AML requires the
clonal acquisition of addition genetic mutations.60
Familial AML with germline mutant CEBPA (OMIM 11697) is
inherited (autosomal dominant) and has nearly complete pene-
trance for development of AML.54,56 AML can develop anytime
from the age of 1 year to old age. The AML is usually associated
with biallelic CEBPA mutations, usually the first mutation is
germline and often at the 5′ end of the gene, and the second
mutation occurs in the second allele often in the 3′ region of the
gene. This is similar to what is observed in those with somatic
mutations of CEBPA (de novo AML). CEBPA is critical for myeloid
proliferation and granulocytic differentiation. Most of these
patients have a normal karyotype when they develop AML; and
they have a relatively favorable prognosis with 50–60% that may
be cured. The AML is often FAB subtype M1 or M2, with aberrant
CD7 expression on the blast cells and often a N-RAS mutation
present in the blast cells. As expected, siblings of the proband
with the germline CEBPA mutation have a 50% risk of also carrying
the mutation.
Familial platelet disorder (FPD), (OMIM 601399) with a
propensity to AML is caused by a germline mutation of RUNX1.
The RUNX1 gene is important for myeloid proliferation and
differentiation; and its alteration in FPD is either a deletion, a loss
of function missense mutation or occasionally a dominant-
negative missense mutation. These individuals often have a low
peripheral blood platelet count, a functional platelet disorder and
GCSF hypersensitivity of their myeloid cells.52,61 The frequency of
developing AML with FPD is about 40%, and AML can occur at any
age but more often between 40 and 70 years of age.
AML that develops in FPD individuals do not acquire NPM1 or
FLT3 mutations, which are frequently found in de novo AML. A
recent study found that asymptomatic RUNX1 carriers can harbor
additional somatic mutations with a mean VAF varying between
20 and 45%, suggesting that clonal skewed hematopoiesis
frequently precedes the development of overt MDS or AML.60
All asymptomatic RUNX1 carriers were less than the age of 50. By
the age of 50 years, clonal hematopoiesis was easily found in 80%
of RUNX1 carriers.60 One Japanese study reported that these
patients had frequent mutations of the CDC25C gene when they
progressed to AML.62 However, this mutation could not be
detected by other investigators.60,63 This could represent ethnic
differences. The number of mutations in the blast cells found at
the time of AML varies between 8 and 18. The VAF of these
mutations in both the MDS and AML phases of FPD were
comparable (approximately 15–45%).60,61,64
Another germline alteration is a heterozygous mutation of the
transcription factor GATA2. These individuals often have periph-
eral blood eosinophilia, deficiency of monocytes, B cells and
natural killer cells and an increased incidence of non-tuberculosis
mycobacteria and other opportunistic infections including papil-
loma virus.53,55,65–67 The syndrome is often called (MonoMAC).
These patients in addition can develop leg lymphedema and
monosomy 7 (Emberger syndrome). The predilection to develop
MDS or AML is about 70% with a median age of 29 years, but AML
can develop over a wide time span (0.4 to 78 years). Their MDS
phase is often characterized as chronic myelomonocytic leukemia.
The progression to AML is associated with an initial cytopenias
often followed by monosomy 7 (30%) which appears to occur
before an ASXL1 mutation (29% of cases). Interestingly, this latter
mutation occurs only in females, who are often young; it is
associated with a bad prognosis.68,69 Another frequent secondary
mutation is NRAS, but other Driver mutations have been noted
including RUNX1, STAG2, IDH2, TP53 and SETDB1. Transformation is
often to a hypercellular fibrotic AML.
Clearly, more experience is required to determine at what
stage these individual with germline preleukemic mutations need
aggressive therapy. Monitoring their marrow for the acquisition of
additional Driver mutations might prompt initiation of aggressive
therapy such as allogenic hematopoietic stem cell transplant.60
If a sibling allotransplant is contemplated, germline DNA sequen-
cing of the donor for the germline mutation is required because
the sibling has a 50% chance of also having the germline
mutation. The ability to take fibroblasts from patients with
germline mutations, induced dedifferentiation to pluripotent stem
cells (iPSC), correct the mutation and then induce these cells to
differentiate into functional hematopoietic stem cell, has been
done.70,71 However, to date, full hematopoietic reconstitution
in vivo has not been possible using the iPSC technique.
Furthermore, gene therapy to repair directly the hematopoietic
cells is a distant dream with a multitude of barriers because unlike
treating sickle cell anemia or thalassemia, every cell must be
corrected.
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THERAPY-RELATED PRELEUKEMIA
Several types of therapy-(mutagen)-related MDS/AML have been
identified. One that almost always has a preleukemic (MDS) phase
is associated with exposure to either alkylating agents (85%),
radiation or selected carcinogens, such as benzene.72–74 Most
frequently an individual with Hodgkin disease, non-Hodgkin
disease, breast cancer, multiple myeloma and so on receives an
alkylating agent and approximately 4 years later develops MDS.
The incidence of therapy-related preleukemia varies from o1 to
10% depending on type of agent administered and the intensity
of the therapy for the initial cancer.72,75–78 Their preleukemic
marrow often (470%) has deletion of either the long arm or the
entire chromosome 5 and/or 7; or they develop a complex
karyotype (⩾3 abnormalities).75,79–81 Some of the frequently
mutated genes in this type of preleukemia includes p53, PTPN11
and the ABC family of genes. The p53 mutation often occurs early
in the course of MDS. A second group of mutations are commonly
associated with secondary AML (Table 1). In contrast to de novo
acute leukemia, mutations of NPM1, CEBPA or FLT3 are
infrequent.30,72,82–84 The RAEB and RAEB-t subgroups are fre-
quently linked to therapy-related preleukmia (73%).85 These
individuals almost always progress to AML with a mean duration
of the preleukemic phase of 11.2 months.86–88 They have a poor
prognosis (survival with AMLo6–8 months).73,75,89 Treatment for
these individuals when AML develops has a number of clinical
challenges including a greater number of co-morbidities,
decreased organ reserve from either previous therapy or primary
disease and a higher incidence of unfavorable cytogenetic
changes. The key prognostic factors in therapy-related MDS/AML
are patient’s age, performance status and karyotype. Because of
their poor outcome, intensive chemotherapy with allogeneic
hematopoietic stem cell transplant should be encouraged.
In summary, the development of unexplained pancytopenia
and the finding of specific karyotypic abnormalities (loss of
chromosome 5 and/or 7 or their long arms in the marrow) in
patients who received chemotherapy and/or radiation therapy for
another disease about 4 years earlier is pathognomonic of
preleukemia. Evolution to overt leukemia is almost universal if
the preleukemic individual survives the complications of hemor-
rhage and infection. Therapy preleukemia can be viewed as an
early phase of therapy AML in which the malignant hematopoietic
clone is established and becomes predominant.
The second type of therapy-related AML develops in individuals
whose initial malignancy was treated with a topoisomerase II inhibitor
(for example, etoposide, doxorubicin, mitoxantrone).72,90,91 Typical
latency period from therapy to AML is a median of 33 months but can
be as short as 12 months. The AML often has a chromosomal
translocation especially at 11q23 (MLL gene) or chromosome 21q22
(RUNX1). The morphologic phenotype often is FAB M4 or M5. These
individuals usually do not have a MDS (preleukemic) phase. Overall
survival of these individuals after development of AML is equal to that
of a patient with de novo leukemia having the same cytogenetic
abnormalities in their AML cells.
PRELEUKEMIA IN MORPHOLOGIC COMPLETE REMISSION
AFTER AML CHEMOTHERAPY
During the 1980s and the early 1990s, studies by Phil Fialkow and
Claus Bartram noted that about ¼ of AML patients who achieved
complete morphologic remission by chemotherapy, continued to
have an abnormal clone as measured by X-inactivation.31 This has
been buttress by studies showing strong association between
persistent karyotypic markers of AML in first complete morpho-
logic remission. Hence, the term ‘preleukemic clone’ has been
used to describe the loss of the major phenotype of AML (Driver
mutations associated with AML blast cells), but where the clonal
hematopoiesis persisted, and could evolve into relapse AML. Thus,
the term preleukemia is used in a very different context than
utilized in the 1950s and 1960s.
High throughput sequencing of AML samples reinforced the
concept that a preleukemic clone can exist at the time of
complete morphologic remission after standard aggressive
chemotherapy for AML. Individuals whose AML cells at diagnosis
had mutations of either DNMT3A, IDH2, TET2, UAF1 or SRSF2 often
had the same alteration at complete morphologic remission.92–98
In contrast, more classical Driver (pan-AML) mutations such as
FLT3, RUNX1, RAS, NPM1, CEBPA and WT1 genes, although present
at diagnosis of AML, were no longer found in complete remission.
Dr. Ley’s group reported that 21/37 individuals whose AML cells
carried DNMT3A, TET2 or IDH1/2 mutations at diagnosis, continued
to have the same mutation in 45% of the hematopoietic cells at
complete morphologic remission; but the classical Driver muta-
tions (for example, NPM1, FLT3 and RAS) found at diagnosis, were
not detectable at remission.94 Of note, if the individual had a
persistence of a mutation at complete remission (day 30 after
induction therapy), their event-free survival was 6 months and
their overall survival was 10 months as compared with an event-
free survival of 18 months and an overall survival of 42 months in
individuals with no mutation in the 30-day complete remission
marrow.
Another study focused on DNMT3A mutations. The investigators
noted that the DNMT3Amutation was often present in the marrow
cells in complete morphologic remission at an allele frequency of
1-50% and could be detected even 8 years after initial complete
remission of AML with no other molecular markers of AML.
Likewise, the mutations could be found at a lower allele frequency
in T and B lymphocytes in the same patients.97 The authors
concluded that DNMT3A mutations precede NPM1 and FLT3-ITD
mutations in AML pathogenesis; and the fact that this mutation
can be found in B and T cells suggest that it involves a very early
hematopoietic stem cell that can differentiate both into lymphoid
and myeloid cells.93,97
Dr. Dick’s group studied a cohort of individuals whose AML
blast cells had mutations of DNMT3A and NPM1 at both diagnosis
and relapse.93 In morpholoigc complete remission, only the
DNMT3A mutation could be found. In a second part of the study,
human bone marrow cells at diagnosis of AML (264 samples) were
injected into immunodeficient mice (NSG mice). A total of 37% of
samples did not engraft, 40% of samples recapitulated the AML
blasts in the mice; but most interestingly, 23% of the samples
produced multi-lineage engraftment that appeared normal, but
continued to have mutations of either DNMT3A or IDH1/2.93 This
suggests that even at diagnosis of AML, a preleukemic clone
exists. Interestingly, the same group also purified different stages
of hematopoietic cells at diagnosis of AML whose blasts cells were
marked with both DNMT3A and NPM1 mutations.93 The very early
common hematopoietic progenitors carried the mutation of
DNMT3A, but not NPM1. In contrast, the more mature myeloid
progenitor cells (granulocyte-monocyte progenitors), as well as
the AML blast cells had both the DNMT3A and NPM1 mutations
(Figure 1 summarizes these studies).
A very detailed study focused on IDH2 found that about 22% of
individuals with an IDH2 mutant allele at diagnosis of sAML
continued to have the mutational clone in complete morphologic
remission after chemotherapy; but with marrow transplant, these
aberrant alleles were destroyed.98 In addition, the VAF of the
mutant IDH2 clone exceeded the VAF of the NPM1 or FLT3 clones
in frank AML, and the NPM1 and FLT3 clones disappeared with
complete remission. Colony assays of CD34+ hematopoietic stem
cells and progenitor cells were done in complete remission and
96% and 50% of the erythroid and granulocyte macrophage
colonies, respectively, had only the IDH2 mutation. Further, colony
and single-cell-nucleotide sequencing also confirmed that
DNMT3A, TET2 and ASXL1 were early clonal mutations during
evolution to AML.99,100
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Interestingly, recent studies found a rapid expansion of a pre-
existing non-leukemic/preleukemic mutant hematopoietic clone
occurred following induction therapy for de novo AML.101,102
Investigators discovered that at diagnosis of AML, a small, barely
detectable, non-leukemic clone was overshadowed by the
leukemic clone. After remission inducing chemotherapy, the
non-leukemic/preleukemic clone markedly expanded (VAF of
20–40%) compared with the normal hematopoietic population.
Thus, the non-leukemic/preleukemic mutant clones had a
competitive advantage over the normal hematopoietic cells.
These studies highlight the importance to distinguish Driver-
related leukemia versus non-leukemic/preleukemic mutant popu-
lations when the physician assesses by DNA sequencing the
response to induction chemotherapy.
PRELEUKEMIC STEM CELLS AND THERAPEUTIC IMPLICATIONS
A long-lasting preleukemic (MDS) clone often marked by
mutations of either DNMT3A, TET2 IDH1/2 or a spliceosome gene,
can have a competitive growth advantage over the normal
hematopoietic cells. These mutations can cause ineffective
hematopoiesis. This can be followed by a subclone that develops
a major Driver mutation (for example, NPM1) or fusion gene,
resulting in frank AML with blast cells. These Driver (pan-AML)
mutations block differentiation providing these cells with a
proliferative advantage and causing life-threatening peripheral
blood cytopenias. After ablative chemotherapy accompanied by a
complete morphologic remission, the preleukemic clone may
persist suggesting that these cells are resistant to standard
chemotherapy, but are still able to differentiate to normal-
appearing mature blood cells. If frank AML reoccurs, the original
or new blastic AML subclone emerges from the preleukemic clone.
Event-free survival of individuals with a preleukemic clone at
morphologic complete remission, is inferior to those with no
preleukemic clone during complete remission.30,94 Perhaps,
therapeutic intervention might be considered while these patients
are in complete morphologic remission if nucleotide monitoring
shows the acquisition of a Driver mutation.103 This might prompt
hematopoietic transplantation before frank AML develops
(Figure 2). Timing will be critical because reports have found that
the preleukemic clone may be present for 8–10 years without
emergence of relapsed blastic AML. Repeat targeted nucleotide
sequencing of the marrow may be no more expensive than
cytogenetic examination; and in the future sequencing may
supplant cytogenetics in define circumstances.
IDH2 mutant AML cells can generate D-2-hydroglycolate (D-2-
HG) as a marker of the mutation.98 The plasma level of this
compound is high in AML patients; however, those in complete
morphologic remission with a mutant IDH2 clone may also have
elevated serum D-2-HG. Therefore, measuring D-2-HG is not a
good surrogate for making clinical decisions.98 Specific pharma-
cologic inhibitors of IDH2 have been developed. IDH2 mutation is
often in the founder mutant clone; this clone acquires a Driver
mutation to develop frank AML. The ability of the IDH2 inhibitor to
eliminate the AML or founder clone requires further study.
Of interest, mathematic modeling noted a good correlation
between the lifetime risk of developing cancer and the number of
stem cell division that specific tissue undergoes during an
individual’s lifespan.104,105 Mutations are passed to daughter cells
only at cell division. Normal cells undergo about 1 mutation per
108 cell divisions. An estimated 11 000 to 22 000 early hemato-
poietic stem cells are present in an individual. This number
decreases with age. Indeed, a likely hypothesis is the fewer
hematopoietic stem cells that are present as an individual ages,
the greater their proliferative pool to maintain normal peripheral
blood counts; hence, the greater chance for a mutational
Figure 1. Schematic diagram of the hematopoietic tree with stem cells having a preleukemic mutation (DNMT3A) and blast cells acquiring a
Driver (pan-AML) mutation (NPM1 mutation), and retaining the DNMT3A mutations. Black dot, DNMT3A mutation; Red dot, NPM1 mutation.
Figure summarizes data by John Dick’s lab.93
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event.104,105 Many of the random mutations that occur in these
cells affect non-critical genes (passenger genes) providing no
growth advantage to these stem cells. Thus, ‘bad luck’ happens
when a mutation occurs in a gene that provides a proliferative
advantage to the hematopoietic cell. The resulting clone of cells
has a greater chance to acquire additional mutations that might
evolve into frank AML.
SUMMARY
In summary, the term ‘preleukemia’ has evolved over the years.
Initially in the 1950s and 1960s, preleukemia was viewed as MDS.
We now know that the clinical course as well as chromosomal and
mutational changes of MDS are often markedly different from
those present in de novo AML. Individuals with an inherited
mutation of RUNX1, GATA2 or C/EBP in their germline have a very
high chance of developing AML; and thus have a preleukemic
mutation. Also, previous treatment of a primary malignancy with
either an alkylating drug or radiation therapy can result in a
preleukemia that almost always progresses to AML. As outlined
in Figure 3, very early hematopoietic stem cells can develop
mutations that results in clonal hematopoiesis especially in those
460 years of age. In hematopoietically normal older individuals,
this clone probably should not be called preleukemic. The
incidence of evolution to AML in these individuals requires further
study, but may be 0.5 to 1% per year. Quizzically, the mutations
associated with MDS are often the same as those observed both in
the normal elderly individual as well as the preleukemic clone in
AML patients who are in morphologic complete remission.
Development of overt AML requires Driver mutations. X-inactiva-
tion and DNA-sequencing studies showed that AML patients
that obtained a complete morphologic remission can retain a
preleukemic clone suggesting that these cells are resistant to
normal ablative chemotherapy perhaps because they involve
quiescent hematopoietic stem cells not easily killed by our
standard chemotherapy. Patients whose leukemia evolves from an
ancestral preleukemic clone, often will require therapy that
exceeds our standard chemotherapy and perhaps monitoring of
the preleukmic clone for acquisition of Driver mutations during
remission may help to determine when aggressive therapy should
be initiated. In conclusion, preleukemia might be defined as a
condition that has modifying mutations in the bone marrow that
either cause MDS or cause clonal hematopoietic expansion initially
without disease but associated with progression to AML.
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